BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Accelovance Reports 2010 Growth; Shares Outlook for 2011


2/18/2011 11:38:23 AM

Rockville, MD – February 18, 2011 – Accelovance, a privately held clinical research organization reported its sixth year of continued revenue growth after closing out a successful 2010. The year included an award of two Phase III rescue studies; several contracts with biotech companies initiating Phase I and Phase II clinical programs; and new relationships with government-funded Sponsors. Accelovance also gained continued industry recognition for its best-in-class services with a second, consecutive “BEST CRO” ViE Award.

“The past 12 months have been remarkable, with 30% top line growth over last year. We are proud of the efficiencies our enhanced study management has to offer,” commented Steve Trevisan, President and CEO of Accelovance. “Revenue growth and industry awards support our ability to deliver clinical solutions through a flexible offering of a CRO, Clinical Sites, Patient Recruitment and Clinical Call Center.” In 2010, the Washington Business Journal added Accelovance to its annual list of 50 Washington-area Fastest Growing Companies.

New programs will capitalize on Accelovance’s integrated service approach; CRO, sites and recruitment solutions within our core market of vaccines, immunology and primary care conditions. The CRO division will continue to focus on the business needs of biotech and small/mid pharma with expanded areas of expertise in oncology, cardiovascular and cell/gene therapy. An increased interest in Accelovance’s Clinical Call Center to support retention, compliance, recruitment efforts and observational studies for Large Pharma indicates additional growth opportunities over the next 12-18 months.

“A flexible, innovative offering that can be utilized by Sponsors big and small alike gives Accelovance a diverse client base that will support overall corporate growth,” commented Trevisan. Accelovance also had a 15% increase in employees to support new programs and expanded therapeutic expertise. Similar hiring activity is anticipated for 2011.

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. The Company tailors its offering of a full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets Sponsors’ needs. Accelovance’s ownership and operation of six (6) research-dedicated clinical sites provides operational insight to study conduct and patient recruitment that other CROs never acquire. Additionally, Accelovance has a wholly owned subsidiary providing regulatory consulting and CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.

For more information, visit the company’s website at http://www.accelovance.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES